Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Article About Injectable Minoxidil for Hair Loss Disorders: A Systematic ReviewFeatured ArticlesThe Latest
December 12, 2024

Injectable Minoxidil for Hair Loss Disorders: A Systematic Review

JDD Latest News Could injectable minoxidil revolutionize hair loss management? While widely used in topical and oral forms, its injectable counterpart is garnering attention for treating conditions like androgenetic alopecia and…
Journal of Drugs in Dermatology JDD Article About Practical Update on Treatment of Oral CandidiasisFeatured ArticlesThe Latest
December 11, 2024

Practical Update on Treatment of Oral Candidiasis

JDD Online Exclusive As new psoriasis treatments expand, so do potential side effects like oral candidiasis. This common yet manageable condition may present with distinctive symptoms, such as burning sensations or…
Journal of Drugs in Dermatology JDD Article About Recognizing and Advancing Leadership in Dermatology: Promoting the Health Care Administration, Leadership, and Management SubspecialtyFeatured ArticlesThe Latest
December 9, 2024

Recognizing and Advancing Leadership in Dermatology: Promoting the Health Care Administration, Leadership, and Management Subspecialty

JDD Article Highlights The launch of the Health Care Administration Leadership and Management (HALM) subspecialty in 2023 is poised to redefine leadership in dermatology. Supported by the American Board of…

Leave a Reply